Sonex Health specializes in ultrasound-guided treatment of common orthopedic syndromes affecting the extremities. Its proprietary devices enable surgeons to use real-time ultrasound guidance to visualize critical anatomy, reducing invasiveness and cost of care and enabling faster patient recovery. The company’s first commercial device, UltraGuideCTR, for carpal tunnel syndrome, received FDA clearance in 2019. Its second commercial device, UltraGuideTFR, designed to treat trigger finger, was released in 2022. Sonex intends to use proceeds from the financing to expand access to these commercially available devices and broaden patient treatment for CTS and TF. The company is led by president and CEO Bob Paulson.

Total raised

$40M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2023